Research programme: antibacterials - Galapagos/LEO Pharma

Drug Profile

Research programme: antibacterials - Galapagos/LEO Pharma

Latest Information Update: 15 Apr 2014

Price : $50

At a glance

  • Originator Galapagos NV; LEO Pharma
  • Developer BioFocus DPI
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 15 Apr 2014 Discontinued - Preclinical for Bacterial infections in Denmark (unspecified route)
  • 15 Apr 2014 Discontinued - Preclinical for Bacterial infections in Belgium (unspecified route)
  • 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top